- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04730232
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
October 22, 2021 updated by: Tianjin Medical University Second Hospital
An Open Label, Single-arm, Phase 2 Study of Tislelizumab Combined With Nab-Paclitaxel for Patients With High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not completely resectable.
Patients will receive treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for 4 treatment cycles over 12 weeks followed by transurethral resection biopsy.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
63
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hailong Hu, MD,PhD
- Phone Number: +86-13662096232
- Email: hhllove2004@163.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300211
- Recruiting
- Tianjin Medical University Second Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Willing and able to provide written informed consent;
- Ability to comply with the protocol;
- Age ≥ 18 years;
High-risk non-muscle-invasive urothelial carcinoma or high-risk non-muscle-invasive urothelial carcinoma as the main pathological component > 50%, difined as following:
a. T1 b. High-grade Ta c.Carcinoma in situ(CIS);
- Multi-point biopsy of bladder shows there are more than 2 section and over 3 points of pathological specimens are diagnosed as above, meanwhile, the tumor has to be diagnosed as not completely resectable by at least 2 senior urologist;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2;
- Agreed to provide tissue examination samples (for detection of PD-L1 expression, tumor mutation load, IHC, detection of DNA and RNA, etc;)
Organ function level must meet the following requirements:
- Hematological indexes: neutrophil count >= 1.5x10^9/L, platelet count >= 80x10^9/L, hemoglobin >= 6.0 g/dl (can be maintained by blood transfusion);
- Liver function: total bilirubin <=1.5 ULN, alanine aminotransferase and aspartate aminotransferase <=2.5 ULN;
- The subjects volunteered to join the study, signed informed consent, and had good compliance with follow-up;
Exclusion Criteria:
- Receive live attenuated vaccine within 4 weeks before treatment or during the study period;
- Active, known or suspected autoimmune diseases;
- History of primary immunodeficiency;
- Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
- Pregnant or lactating female patients;
- Untreated acute or chronic active hepatitis B or hepatitis C infection. Under the condition of monitoring the virus copy number of patients receiving antiviral treatment, doctors can judge whether they are in line with the patients' individual conditions;
- Prior use of immunosuppressive drugs within 4 weeks prior to the start of treatment, excluding nasal and inhaled corticosteroids or physiological doses of systemic steroids (i.e. not more than 10 mg / day prednisolone or other corticosteroids with the same physiological dose);
- Known or suspected allergy to tislelizumab and albumin paclitaxel;
- Have a clear history of active tuberculosis;
- Received PD-1 / PD-L1 / CTLA-4 antibody or other immunotherapy in the past;
- Participating in other clinical researchers;
- Men with reproductive capacity or women who are likely to become pregnant do not take reliable contraceptive measures;
Uncontrolled concurrent diseases, including but not limited to:
- HIV infected (HIV antibody positive);
- Severe infection in active stage or poorly controlled;
- Evidence of serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension [i.e. hypertension greater than or equal to CTCAE grade 2 after drug treatment]);
- Patients with active bleeding or new thrombotic disease.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tislelizumab and Nab-Paclitaxel
Tislelizumab 200mg IV on day 1 in combination with nab-paclitaxel 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy.
|
Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles.
Other Names:
Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete Response (CR) Rate for tilelizumab combined with nab-paclitaxel
Time Frame: At the time of transurethral resection biopsy (within 9 or 12 weeks of the first dose of tislelizumab)
|
At the time of transurethral resection biopsy (within 9 or 12 weeks of the first dose of tislelizumab)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR)
Time Frame: up to 3 years
|
up to 3 years
|
|
Number of adverse events and severity by grade (CTCAE)
Time Frame: 12 weeks of treatment plus 30 days for toxicity followup
|
Safety and toxicity will be characterized according to the reported adverse event (AE) profile using NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0, as well as a patient questionnaire derived from the Patient Reported Outcomes (PRO)-CTCAE and Patient Reported Outcomes Measurement Information System (PROMIS).
|
12 weeks of treatment plus 30 days for toxicity followup
|
Cystectomy-Free Survival (CFS)
Time Frame: up to 3 years
|
defined from D1 of treatment until cystectomy.
|
up to 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Hailong Hu, MD,PhD, Tianjin Medical University Second Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 27, 2020
Primary Completion (Anticipated)
February 1, 2024
Study Completion (Anticipated)
July 1, 2024
Study Registration Dates
First Submitted
January 25, 2021
First Submitted That Met QC Criteria
January 25, 2021
First Posted (Actual)
January 29, 2021
Study Record Updates
Last Update Posted (Actual)
October 29, 2021
Last Update Submitted That Met QC Criteria
October 22, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Carcinoma
- Urinary Bladder Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Paclitaxel
Other Study ID Numbers
- Truce-02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Muscle Invasive Bladder Urothelial Carcinoma
-
University of Roma La SapienzaNot yet recruitingNon-muscle-invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial Carcinoma | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
-
National Cancer Institute (NCI)Not yet recruitingNon-Muscle Invasive Bladder Urothelial Carcinoma | Recurrent Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
IRCCS San RaffaeleRecruitingBladder Cancer | Bladder Disease | Bladder Cancer Recurrent | Bladder Urothelial Carcinoma | Non Muscle Invasive Bladder Cancer | Bladder Neoplasm | Non-Muscle Invasive Bladder Urothelial Carcinoma | Non-Muscle Invasive Bladder Neoplasms | Bladder Cancer Stage I, With Cancer in Situ | Bladder Urothelial... and other conditionsItaly
-
Clinique Beau SoleilCepheid; Team Languedoc Mutualité / Nouvelles technologiesCompletedNon-Invasive Bladder Urothelial Carcinoma | Non-Invasive Bladder Papillary Urothelial Carcinoma, Low Grade | Non-Invasive Bladder Papillary Urothelial Carcinoma, High GradeFrance
-
Nucleix Ltd.CompletedNon Muscle Invasive Bladder Cancer | Non-Muscle Invasive Bladder Urothelial CarcinomaUnited States
-
AstraZenecaHospital Israelita Albert EinsteinRecruitingUrothelial Carcinoma | Muscle-invasive Bladder Cancer | Non Muscle Invasive Bladder CancerBrazil
-
Tyra Biosciences, IncRecruitingSolid Tumor | Bladder Cancer | Advanced Solid Tumor | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | FGFR3 Gene Mutation | Urinary Tract Cancer | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Non-muscle-invasive Bladder Cancer | FGFR3 Gene Alteration | Urinary... and other conditionsAustralia, United States, France, Spain
-
National Cancer Institute (NCI)Canadian Cancer Trials GroupActive, not recruitingAtezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder CancerRecurrent Bladder Urothelial Carcinoma | Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage I Bladder Urothelial Carcinoma AJCC v6 and v7United States, Canada
-
UroGen Pharma Ltd.TerminatedBladder Cancer | Urothelial Carcinoma Bladder | Urothelial CarcinomaUnited States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
-
CG Oncology, Inc.RecruitingBladder Cancer | Urothelial Carcinoma | Urologic Cancer | Non Muscle Invasive Bladder CancerUnited States
Clinical Trials on Tislelizumab
-
Peking University Cancer Hospital & InstituteRecruitingNon-small Cell Lung Cancer | Consolidation Immunotherapy | Radiotherapy or Sequential ChemoradiationChina
-
Jiangsu Yahong Meditech Co., Ltd aka AsierisRecruitingMuscle Invasive Bladder CancerUnited States, China
-
Fudan UniversityActive, not recruitingHepatocellular CarcinomaChina
-
Henan Cancer HospitalNot yet recruiting
-
Shanghai Gopherwood Biotech Co., Ltd.RecruitingAdvanced Solid TumorChina
-
GeneScience Pharmaceuticals Co., Ltd.RecruitingMalignant Solid TumorsChina
-
Fudan UniversityRecruitingRefractory Malignant AscitesChina
-
Peter MacCallum Cancer Centre, AustraliaRecruiting
-
Peking UniversityRecruitingGastric Cancer | Colo-rectal CancerChina
-
Fudan UniversityNot yet recruiting